白蛋白结合型紫杉醇治疗宫颈鳞癌的近期疗效和不良反应分析  

Analysis of the Short-Term Efficacy and Adverse Reactions of Albumin-Bound Paclitaxel in the Treatment of Cervical Squamous Cell Carcinoma

作　　者：吴嘉纯 朱莺[1] 邹美英[1] 武雅琴[1] 周超 WU Jiachun;ZHU Ying;ZOU Meiying(Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research,Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Nanjing 210009,China)

机构地区：[1]江苏省肿瘤医院/江苏省肿瘤防治研究所/南京医科大学附属肿瘤医院,江苏南京210009

出　　处：《河北医学》2024年第6期1040-1044,共5页Hebei Medicine

基　　金：2021年度江苏省妇幼健康科研项目,(编号:F202165)。

摘　　要：目的:探究白蛋白结合型紫杉醇治疗宫颈鳞癌的近期疗效和不良反应。方法:选取2019年10月至2022年10月我院就诊124例宫颈鳞癌患者为受试对象,采用简单随机化法分为两组(观察组62例和对照组62例)。两组均给予放疗处理,对照组采用紫杉醇联合顺铂,观察组予以白蛋白结合型紫杉醇与顺铂。记录治疗4个周期后两组患者临床效果及治疗期间毒副反应发生情况,比较治疗前、治疗4个周期后两组血清肿瘤标志物[鳞状细胞癌抗原(SCCA)、癌胚抗原(CEA)、糖类抗原(CA125)]、T淋巴细胞水平(CD3^(+)、CD4^(+)、CD8^(+))的变化。结果:治疗4个周期后,观察组治疗有效率更高(P<0.05),两组治疗期间毒副反应出现情况差异无统计学意义(P>0.05)。治疗4个周期后两组血清SCCA、CEA、CA125水平均降低,且观察组降低幅度更显著(P<0.05)。治疗4个周期后,两组血清CD3^(+)、CD4^(+)水平均降低,对照组降低幅度更显著,CD8^(+)均升高,对照组升高幅度更显著(P<0.05)。结论:白蛋白结合型紫杉醇用于宫颈鳞癌疾病其疗效显著,可有效控制宫颈鳞癌进展,且安全性较高,适合临床推广。Objective:To investigate the short-term efficacy and adverse reactions of albumin-bound paclitaxel in the treatment of cervical squamous cell carcinoma.Methods:From October 2019 to October 2022,124 patients with cervical squamous cell carcinoma treated at our hospital were selected as subjects and randomly divided into two groups(observation group with 62 cases and control group with 62 cases).Both groups received radiotherapy;the control group was treated with paclitaxel combined with cisplatin,while the observation group was given albumin-bound paclitaxel combined with cisplatin.Clinical efficacy and occurrence of toxic side effects during treatment were recorded after four cycles.Changes in serum tumor markers[squamous cell carcinoma antigen(SCCA),carcinoembryonic antigen(CEA),carbohydrate antigen(CA125)]and T lymphocyte levels(CD3^(+),CD4^(+),CD8^(+))before and after four cycles of treatment were compared between the two groups.Results:After four cycles of treatment,the observation group had a higher treatment efficacy rate(P<0.05).There was no statistically significant difference in the occurrence of toxic side effects between the two groups during treatment(P>0.05).Serum levels of SCCA,CEA,and CA125 decreased in both groups after four cycles of treatment,with a more significant decrease in the observation group(P<0.05).Serum levels of CD3^(+)and CD4^(+)decreased in both groups,with a more significant decrease in the control group,while CD8^(+)levels increased,with a more significant increase in the control group(P<0.05).Conclusion:Albumin-bound paclitaxel is significantly effective in treating cervical squamous cell carcinoma,can effectively control the progression of the disease,and has high safety,making it suitable for clinical promotion.

关 键 词：白蛋白结合型紫杉醇 宫颈鳞癌 肿瘤标志物 毒副反应 淋巴细胞 

分 类 号：R737.33[医药卫生—肿瘤]